SCHEMBL4812159

SCHEMBL4812159

COc1ccc(C(c2ccc(OC)cc2)n2nc(-c3ccsc3)c3c2-c2cc(CNC(=O)CN4CCCC4)ccc2C3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
CNR1 P21554 1/20 0.37
KIT P10721 3/20 0.37
FLT1 P17948 2/20 0.37
KDR P35968 2/20 0.37
FLT4 P35916 1/20 0.37
TEK Q02763 1/20 0.37
POLB P06746 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
PDGFRB P09619 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4810667 0.94 LMNA (0.42) LMNASMN1; SMN2TSHRALDH1A1MAPT
SCHEMBL5929631 0.94 LMNA (0.42) LMNASMN1; SMN2TSHRALDH1A1MAPT
SCHEMBL4816463 0.90 PTGES (0.37) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4817848 0.90 LMNA (0.42) LMNASMN1; SMN2TSHRALDH1A1MAPT
SCHEMBL4816274 0.89 PTGES (0.37) LMNAALDH1A1MAPTCNR1KIT
SCHEMBL4807491 0.89 LMNA (0.36) LMNASMN1; SMN2ALDH1A1MAPTCNR1
SCHEMBL4814988 0.88 ALDH1A1 (0.39) LMNATSHRALDH1A1MAPTKIT
SCHEMBL4810260 0.85 CNR1 (0.39) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4817756 0.85 KDR (0.36) CNR1KITFLT1KDRFLT4
SCHEMBL4820064 0.85 LMNA (0.43) LMNASMN1; SMN2ALDH1A1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 EP disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 US disclosed
EP-1740579-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2007-01-10 EP disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 US disclosed
WO-2005095387-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 LMNA 3952/4885SMN1; SMN2 4830/4885TSHR 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.